AI-Powered Neoantigen Discovery Platform
LNEA™ integrates tumor-normal sequencing, somatic mutation identification, HLA typing, MHC-binding prediction, immunogenicity assessment and target prioritization to identify patient-specific therapeutic neoantigens.
Tumor & normal tissue sequencing
Somatic mutation identification HLA typing
Candidate neoantigen generation MHC-binding prediction Immunogenicity assessment
Neoantigen ranking Personalized target selection
Personalized Neoantigen mRNA DC Vaccine
Neoantigens are identified based on each patient’s tumor
Selected neoantigen sequences are encoded in a personalized mRNA construct
Personalized neoantigen mRNA is delivered through autologous dendritic cells
Designed to induce neoantigen-specific T-cell responses
Mar 2023NMPA IND clearance
Feb 2025U.S. FDA IND clearance
Personalized Multi-Target Neoantigen-Specific T-Cell Therapy
Targets up to 30 neoantigens to help limit tumor escape
Includes both CD4+ and CD8+ neoantigen-specific T cells
Uses peripheral blood without requiring tumor tissue collection for manufacturing
Develops without the use of gene-editing technologies
From Patient Sample to Personalized Therapy
Tumor and normal tissue sequencing
Mutation identification and neoantigen prediction
Target prioritization and personalized therapeutic design
Personalized GMP manufacturing and release
Patient-specific mRNA vaccine administration
Patient outcome data collection, feedback, and model refinement
